Spyre Therapeutics posts Q3 financial results and outlines clinical milestone progress

Traders Union
All News
Business & Wealth
Companies
Spyre Therapeutics posts Q3 results

Top Stories

Editors' Picks

Stocks

Crypto

Economics

Currencies

Commodities

Business & Wealth

Market Voices

04.11.2026

Spyre Therapeutics posts Q3 financial results and outlines clinical milestone progress — Spyre Therapeutics posts Q3 results

Spyre Therapeutics announced its financial results for the third quarter alongside updates on its business strategy.

The company emphasized ongoing clinical progress and upcoming development milestones in its inflammatory bowel disease (IBD) and hidradenitis suppurativa (HS) programs. Spyre Therapeutics also confirmed it has secured sufficient financial resources to continue advancing its development pipeline.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Spyre Therapeutics previously secured $350 million in capital for late-stage SPY072 development, bringing its total funding to over $2 billion, according to a recent financing update. The company is also advancing SPY003, a long-acting IL-23 antibody being evaluated for inflammatory bowel disease as both a monotherapy and in combination therapy, as detailed in recent development reports. These efforts support Spyre’s broader pipeline expansion in IBD and related indications.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

#Spyre

Editor's Picks for You

Trustee Founder Vadym Hrusha: The future of crypto payments belongs to AI agents

By Pavlo Kot
10 hours ago

Trustee Founder Vadym Hrusha: The future of crypto payments belongs to AI agents

Editors' Picks

China’s crypto paradox: A booming market despite the ban?

By Alena Volkova
17 hours ago

China’s crypto paradox: A booming market despite the ban?

Editors' Picks

Global Microsoft outage: What happened and how serious is it?

By Mikhail Vnuchkov
Yesterday

Global Microsoft outage: What happened and how serious is it?

Editors' Picks

All Editors' Top Picks

Latest Spyre News

Spyre Therapeutics releases Q3 results and updates after stock ends session up 3.8%

By Mykhailo Ihnatenko
04.11.2026

Spyre Therapeutics releases Q3 results and updates after stock ends session up 3.8%

Companies

Spyre Therapeutics investigates SPY003 as innovative monotherapy and combination approach

By Mykhailo Ihnatenko
27.10.2026

Spyre Therapeutics investigates SPY003 as innovative monotherapy and combination approach

Companies

Spyre Therapeutics presents new clinical and preclinical data for SPY001 002 003 at UEGW2026

By Mikhail Vnuchkov
18.10.2026

Spyre Therapeutics presents new clinical and preclinical data for SPY001 002 003 at UEGW2026

Companies

Pavlo Kot
10 hours ago

Trustee Founder Vadym Hrusha: The future of crypto payments belongs to AI agents

Alena Volkova
17 hours ago

China’s crypto paradox: A booming market despite the ban?

Mikhail Vnuchkov
Yesterday

Global Microsoft outage: What happened and how serious is it?

Dmytro Kharkov
Yesterday

Meme stocks vs. memecoins: Same viral frenzy, different endgames

Anastasiia Chabaniuk
12.11.2026

Better than Bitcoin? The coins that tried to dethrone the king

Daria Chernytska
6 min ago

Ross Gerber: Tesla proposes cybercab with $30,000 price and $300 monthly fee

Pavlo Kot
6 min ago

A lower USD price allows people to acquire more of bitcoin, Adam Livingston notes

Ksenia Gerey
6 min ago

Crypto may remain subdued as industry digests key events, Matt Hougan notes

Elena Nikulina
11 min ago

Bitfinex has worked to expand Bitcoin access for 14 years, Paolo Ardoino notes

Alena Volkova
11 min ago

Gregory Raymond: Bitcoin falls sharply after summer rally

Top News

Jainam Mehta
3 hours ago

Goldman Sachs forecasts 19% return for Asian stocks in 2027

Goldman Sachs forecasts 19% return for Asian stocks in 2027

Sholanke Dele
7 hours ago

Oil prices fall nearly 25% in a month despite Iranian tanker attacks

Oil prices fall nearly 25% in a month despite Iranian tanker attacks

Darina Pashchenko
8 hours ago

Bitcoin plunges below $67,000 as crypto liquidations reach $656 million

Bitcoin plunges below $67,000 as crypto liquidations reach $656 million

Pavlo Kot
10 hours ago

Trustee Founder Vadym Hrusha: The future of crypto payments belongs to AI agents

Trustee Founder Vadym Hrusha: The future of crypto payments belongs to AI agents

Ivan Andriyenko
Yesterday

Bessent warns Fed against aggressive rate hikes amid energy shock

Bessent warns Fed against aggressive rate hikes amid energy shock

Top 5 companies for you

United States

Live News

Mykhailo Ihnatenko
Now

AMD stock faces profit-taking risk as AI momentum builds

Olga Shendetskaya
Now

Eurozone economy outperforms expectations, strengthening case for ECB rate hike

Anton Kharitonov
Now

EUR/USD remains under pressure as dollar strength threatens a drop to 1.1000

Mykhailo Ihnatenko
Now

Ethereum drops below $2,000: Can ETH recover amid $1.64 billion in crypto liquidations?

Pavlo Kot
Now

Indian authorities raid CoinDCX and Delta Exchange over suspicious crypto transactions

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.